074: Phase 3 study of Solifenacin in Children age 2-5 with NDO

• Research type

  Research Study

• Full title

  A Phase 3, Open-Label, Baseline-Controlled, Multi-center, Sequential Dose-Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children from 2 years to less than 5 years of Age with Neurogenic Detrusor Overactivity.

• IRAS ID

  120741

• Contact name

  Prasad Godbole

• Contact email

  prasad.godbole@sch.nhs.uk

• Sponsor organisation

  Astellas Pharma Europe B.V.

• Eudract number

  2012-003178-22

• REC name

  Yorkshire & The Humber - Sheffield Research Ethics Committee

• REC reference

  13/YH/0082

• Date of REC Opinion

  17 Apr 2013

• REC opinion

  Favourable Opinion